コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 into bone marrow and the presence of an IgM monoclonal gammopathy.
2 inosis, extracutaneous manifestations, and a monoclonal gammopathy.
3 coni syndrome (FS) is a rare complication of monoclonal gammopathy.
4 from the sera of individuals with a form of monoclonal gammopathy.
5 for histology in patients who do not have a monoclonal gammopathy.
6 proportion of patients will have persistent monoclonal gammopathy.
7 or hereditary amyloidosis with a concomitant monoclonal gammopathy.
8 um and glutamate than patients with indolent monoclonal gammopathies.
9 by CD138(+) cells across the progression of monoclonal gammopathies.
10 n has been implicated in the pathogenesis of monoclonal gammopathies.
11 se-associated gammopathies and some sporadic monoclonal gammopathies.
12 Gaucher's disease have an increased risk of monoclonal gammopathies.
13 irus (EBV) replication in the persistence of monoclonal gammopathy.1 It has been known for some time
15 se characterized by urticarial exanthema and monoclonal gammopathy accompanied by systemic symptoms s
16 yeloma (CMM) are preceded by an asymptomatic monoclonal gammopathy (AMG), classified as either monocl
18 a B-cell malignancy characterized by an IgM monoclonal gammopathy and bone marrow (BM) infiltration
20 We review the causal association between monoclonal gammopathy and neuropathy, and critically rev
21 fection is unknown, but in many patients the monoclonal gammopathy and other B-cell abnormalities can
22 HIV infection have an increased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The
23 o indicate a causal relationship between the monoclonal gammopathy and the renal damage and because t
24 me is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and b
30 aracterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biol
31 characteristics of human disease, including monoclonal gammopathy, BM infiltration with lytic bone l
33 pared with 2% of age-matched controls, had a monoclonal gammopathy characterized as IgG lambda in 9 p
34 ion disease (MIDD) is a rare complication of monoclonal gammopathy characterized by deposition of mon
37 mune cells in 305 patients with asymptomatic monoclonal gammopathy enrolled in S0120 under the auspic
38 sed on clinical and laboratory findings with monoclonal gammopathy evaluation and, if indicated, TTR
39 ent of peripheral neuropathy associated with monoclonal gammopathies has been advanced by recent clin
40 ) and associated skeletal destruction, serum monoclonal gammopathy, immune suppression, and end-organ
41 phritic factor in child GP patients and with monoclonal gammopathy in adult GP patients, who frequent
43 a cell dyscrasias.2,3 The exact mechanism of monoclonal gammopathy in patients with HIV infection is
45 trosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy
46 onal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolip
47 e that clinical progression in patients with monoclonal gammopathies is associated with an acquired b
48 -stage renal disease, the persistence of the monoclonal gammopathy is associated with high rates of r
52 biopsy in only 15% of patients, included 21 monoclonal gammopathies of renal significance; 15 multip
53 l population can be identified as in myeloma/monoclonal gammopathies of undetermined significance (MG
54 y modified paraprotein target (paratargs) in monoclonal gammopathies of undetermined significance (MG
55 from 61 patients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) w
59 tion process of normal plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) a
60 tribution was determined in 63 patients with monoclonal gammopathy of uncertain significance (MGUS) a
62 from 56 subjects representing premalignant (monoclonal gammopathy of uncertain significance), early,
63 performed CGH on 25 cases of MM, 4 cases of monoclonal gammopathy of uncertain significance, and 1 c
64 as an indolent course of disease that mimics monoclonal gammopathy of undermined significance, wherea
65 ltiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mo
66 34 patients with WM and 10 patients with IgM monoclonal gammopathy of undetermined significance (IgM
67 amples from 58 patients with WM, 77 with IgM monoclonal gammopathy of undetermined significance (IgM-
69 ich evolves from a premalignant stage called monoclonal gammopathy of undetermined significance (MGUS
74 ilial clustering of the precursor condition, monoclonal gammopathy of undetermined significance (MGUS
76 pesticide applicators to assess the risk of monoclonal gammopathy of undetermined significance (MGUS
79 in the etiology of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS
80 e marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS
81 ve cases of multiple myeloma, three cases of monoclonal gammopathy of undetermined significance (MGUS
82 The factors that determine progression from monoclonal gammopathy of undetermined significance (MGUS
85 21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS
86 (MM) are preceded by precursor states termed monoclonal gammopathy of undetermined significance (MGUS
88 thylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS
89 of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS
91 studies have reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS
92 in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS
93 s of premalignant non-immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS
94 ppa or lambda immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS
95 sorting exosomes from multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS
96 rease in CD4+ CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS
98 d for multiple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS
99 receptors on plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS
100 ed in the early pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS
101 The events leading the transformation of the monoclonal gammopathy of undetermined significance (MGUS
104 ression was detected in 5 of 5 patients with monoclonal gammopathy of undetermined significance (MGUS
105 been made to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS
107 previously untreated active myeloma, 14 had monoclonal gammopathy of undetermined significance (MGUS
109 omal aberrations have been identified in the monoclonal gammopathy of undetermined significance (MGUS
110 ewly diagnosed multiple myeloma (MM), 5 with monoclonal gammopathy of undetermined significance (MGUS
111 arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS
112 al similarities to multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS
113 V-8 may play a role in the transformation of monoclonal gammopathy of undetermined significance (MGUS
114 ifferentially expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS
115 ic cells from two out of eight patients with monoclonal gammopathy of undetermined significance (MGUS
116 e multiple myeloma to a benign form known as monoclonal gammopathy of undetermined significance (MGUS
117 g clonal cells in the blood of patients with monoclonal gammopathy of undetermined significance (MGUS
118 olves from a premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS
119 peculated that the clinical progression from monoclonal gammopathy of undetermined significance (MGUS
120 M transformation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS
121 of multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance (MGUS
122 n premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS
123 onsistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS
125 Blood, Farr et al showed that patients with monoclonal gammopathy of undetermined significance (MGUS
126 lonal gammopathy (AMG), classified as either monoclonal gammopathy of undetermined significance (MGUS
127 ressed in bones of a subset of patients with monoclonal gammopathy of undetermined significance (MGUS
130 esson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS
132 was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS
134 old woman with AL-amyloidosis secondary to a monoclonal gammopathy of undetermined significance (MGUS
135 er in these patients is more consistent with monoclonal gammopathy of undetermined significance (MGUS
137 demonstrate an increased fracture risk with monoclonal gammopathy of undetermined significance (MGUS
138 Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS
140 the original clone, referred to as secondary monoclonal gammopathy of undetermined significance (MGUS
141 le myeloma (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS
143 istently preceded by the precursor states of monoclonal gammopathy of undetermined significance (MGUS
144 nce interval [CI], 1.31-17.86; P = .018) and monoclonal gammopathy of undetermined significance (OR,
145 plasma cells (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS
146 with the marrow in preneoplastic gammopathy (monoclonal gammopathy of undetermined significance [MGUS
148 ping phenotypic profiles between AL and both monoclonal gammopathy of undetermined significance and M
149 indeterminate potential (CHIP), analogous to monoclonal gammopathy of undetermined significance and m
150 attern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at di
152 those from healthy donors and patients with monoclonal gammopathy of undetermined significance or ot
153 icroenvironment cells in transformation from monoclonal gammopathy of undetermined significance or sm
154 ecreased serum adiponectin concentrations in monoclonal gammopathy of undetermined significance patie
155 in a pattern that parallels progression from monoclonal gammopathy of undetermined significance to MM
158 n biomarkers can help identify patients with monoclonal gammopathy of undetermined significance who a
159 molecular characteristics that evolves from monoclonal gammopathy of undetermined significance, a hi
160 nguish POEMS from neuropathy associated with monoclonal gammopathy of undetermined significance, addi
161 h light chain amyloidosis, multiple myeloma, monoclonal gammopathy of undetermined significance, and
162 progression from the non-malignant disorder monoclonal gammopathy of undetermined significance, are
163 ight chain amyloidosis, multiple myeloma and monoclonal gammopathy of undetermined significance, immu
165 er than in plasma cells from healthy donors, monoclonal gammopathy of undetermined significance, smol
166 evidence of paraproteinemia in a setting of monoclonal gammopathy of undetermined significance, smol
167 ong 5652 patients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supp
168 e marrow myeloma cells, even in asymptomatic monoclonal gammopathy of undetermined significance.
169 apheresis have shown limited efficacy in IgM monoclonal gammopathy of undetermined significance.
170 neuropathy, myeloproliferative disorder, and monoclonal gammopathy of undetermined significance.
171 ge-progressive premalignant condition termed monoclonal gammopathy of undetermined significance.
173 0%) methylation of SOCS1 and SYK; (5) MM and monoclonal gammopathy of unknown significance (MGUS) had
174 ra from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PB
176 but not in the limited plasma cell disorder monoclonal gammopathy of unknown significance or in nonm
177 onsecutive patients with multiple myeloma or monoclonal gammopathy of unknown significance sequential
178 tomatic MM, 5 with smoldering MM, and 4 with monoclonal gammopathy of unknown significance) and 20 in
182 hat proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however,
185 AL) and multiple myeloma (MM) are 2 distinct monoclonal gammopathies that involve the same cellular c
186 ficance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development o
187 IgG deposits, a form of renal involvement by monoclonal gammopathy that mimics immune-complex glomeru
189 ith end-stage renal disease and known benign monoclonal gammopathy underwent kidney transplantation a
191 rdless of age, is frequently associated with monoclonal gammopathies, which often recognize various m
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。